iMediSync is an AI-based digital mental healthcare platform company founded in Seoul, South Korea in 2012 — a medtech innovator whose mission is to solve the secrets of the brain with AI technology, advancing the diagnosis, monitoring, and treatment of brain-based neuropsychiatric disorders through the integration of brain engineering, artificial intelligence, and the world's largest standardized EEG normative database. The company's product ecosystem centers on two complementary technologies whose combined clinical capability represents one of the most significant advances in accessible neuroscience diagnostics available to mental healthcare providers today.
The iSyncWave is the world's first integrated wireless dry EEG measurement and neurotherapy convergence device — a FDA 510(k)-cleared brain scanning headset that measures brainwave activity without electrode gel, can be worn quickly and comfortably in clinical and non-clinical environments, and transmits high-quality EEG data to the cloud-based iSyncBrain analytics platform in real time. The iSyncBrain platform applies iMediSync's proprietary AI brainwave analysis algorithms — trained on the company's decade-long Life Span EEG Database built in partnership with Seoul National University across ages four to eighty-five — to generate automated cognitive assessment reports, early screening classifications for mild cognitive impairment and dementia, stress and HRV analysis, and the evidence-based digital biomarkers that give clinicians objective, quantitative neurological data in the time frame and the clinical environment that the traditional EEG infrastructure cannot support.
iMediSync's FDA 510(k) clearance for both the iSyncWave device and the iSyncBrain-C software medical device, its ISO 13485 certification, its participation in CES 2021, 2022, and 2023 as one of the most recognized digital health exhibitors at the world's largest consumer technology event, its selection as a Next-Generation Medical Device by the Korean FDA, and its growing North American subsidiary — iMediSync Americas — whose commercial infrastructure supports clinical deployment across the United States, Canada, and Latin America collectively reflect the company's trajectory from Seoul-based AI research venture to globally operating digital mental healthcare platform whose technology is being deployed in clinical practices, research institutions, and healthcare systems across multiple continents.
VID produced event video and virtual broadcast content for iMediSync — the production infrastructure that gave the company the professionally produced digital event presence that a medtech innovator presenting to the global healthcare, research, and investor community requires. For a technology company whose product demonstrations involve the real-time visualization of brainwave data, the clinical validation of AI-generated cognitive assessments, and the specific scientific communication that distinguishes a peer-reviewed medical device company from a consumer health startup, the event video production quality communicates the institutional seriousness and clinical credibility that the target audience of neurologists, psychiatrists, hospital administrators, research partners, and institutional investors evaluates as a proxy for the company's overall quality standard.
The virtual broadcast production methodology VID deployed for iMediSync gave the company the broadcast-quality digital event infrastructure that reaches its globally distributed clinical and research audience without the geographic constraints of in-person event attendance — delivering the iMediSync platform demonstration, the scientific and clinical presentation content, and the company leadership communications to the healthcare professionals, research partners, and institutional stakeholders across the United States, Europe, Asia, and the global markets where iMediSync's diagnostic technology is being evaluated and adopted.
